This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.  Read our Cookies Policy.
Close
Eye News
  • Features
    • Close
    • Features
    • Allied Professions
    • Humanitarian
    • Interviews
    • AI & Oculomics
    • Ophthalmology
    • Optometry
    • Podcast videos
    • Supplements
  • Education
    • Close
    • Education
    • Learning Curve
    • Quiz
    • Top Tips
    • Trainees
    • Medico-Legal
    • The Truth Behind The Headlines
    • Case Reports
    • Pete's Bogus Journey
  • Reviews
    • Close
    • Reviews
    • Book Reviews
    • Journal Reviews
    • What's trending?
    • Tech Reviews
    • My Top Five
    • The Culture Section
  • Events
  • News
  • Product Guide
  • Industry News
  • Contact us
    • Close
    • Contact us
    • Write for Eye News
  • Home
  • Reviews
  • Journal Reviews
  • Use of RAPDx device with optic nerve disease

Use of RAPDx device with optic nerve disease
Reviewed by Claire Howard

1 August 2016 | Claire Howard | EYE - Neuro-ophthalmology | Detection rate, optic nerve disease, relative afferent pupillary defect, standard values

The authors have previously reported on use of the RAPDx device for evaluating relative afferent pupillary defects (RAPD). RAPDx objectively determines the magnitude of RAPD by presenting light stimuli alternately to pairs of eyes with laterality. The parameters of amplitude score and latency score in RAPDx are used to calculate RAPD using log units. The amplitude score is obtained by determining the percentage of constriction of both eyes, whereas the latency score by determining the latency of both eyes. This paper details RAPD evaluations in patient with optic nerve disease, using the previously reported standard values of the amplitude and latency scores. Twenty-eight patients with optic nerve disease were recruited and compared to previously reported data from 84 healthy controls. Amplitude and latency scores were measured using the RAPDx and mean values compared between both groups. In addition, this data was evaluated for correlation with visual acuity and the critical flicker fusion frequency in the optic nerve disease group. Results showed significantly higher scores in the optic nerve disease group than in the control group, for both parameters. The authors conclude that the amplitude and latency scores determined using RAPDx are useful in evaluating RAPD, in particular the standard value of the amplitude score and that future studies should further investigate disease severity, stage and type using a greater sample size.

Evaluation of relative afferent pupillary defect using rapdx device in patients with optic nerve disease.
Satoua T, Ishikawaab H, Asakawab K, et al.
NEURO-OPHTHALMOLOGY
2016;40(3):120-4.
Share This
CONTRIBUTOR
Claire Howard

Salford Royal NHS Foundation Trust, Salford, UK.

View Full Profile
Specialty
  • EYE - Cataract
  • EYE - Cornea
  • EYE - General
  • EYE - Glaucoma
  • EYE - Neuro-ophthalmology
  • EYE - Oculoplastic
  • EYE - Oncology
  • EYE - Orbit
  • EYE - Paediatrics
  • EYE - Pathology
  • EYE - Refractive
  • EYE - Strabismus
  • EYE - Vitreo-Retinal
Archive
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013

Top Of Page

9 Gayfield Square, 
Edinburgh EH1 3NT, UK.

Call: +44 (0)131 557 4184
www.pinpoint-scotland.com

WEBSITE DETAILS
  • Cookie Policy
  • Data Protection Notice
  • Privacy Policy
  • Terms and Conditions
ABOUT US
  • Who we are
  • Register
  • Contact us
  • Contributors
  • Company Awards
DIGITAL ISSUES/GUIDELINES
  • Digital issues - Library
  • Supplements - Library
  • Guidelines
Accreditations
IPSO_FLAG_TEAL 2025.png cpdcertified.png

Pinpoint Scotland Ltd (Registered in Scotland No. SC068684) | © 2025 - Website by Gecko Agency